Health Decisions Receives Safe Harbor Certification
Health Decisions
announced that it received Safe Harbor Certification effective February 15, 2011.
The Safe Harbor designation recognizes Health Decisions meets or exceeds directives of the European Union for data privacy and protection. The Safe Harbor framework was created by the US Department of Commerce in consultation with the Europe Commission's Directive on Data Protection to bridge differences in countries' privacy approaches and provide a streamlined means for US. organizations to comply with data protection laws.
"Health Decisions has always been committed to protecting the confidentiality and privacy of our customer’s data. This certification affirms that commitment," said Health Decisions Chief Operating Officer, Alicia Paladin. "We are pleased to be part of a limited group of organizations to be awarded this designation."
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
